Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nika PharmaceuticalsNIKA 12 9-Day RSI is 76.69 as of Jul. 29, 2026. GuruFocus rates NIKA with a GF Score™ of 12/100. The stock has 3 warning signs investors should review. Among 1,047 Drug Manufacturers companies, Nika Pharmaceuticals ranks worse than 96.85% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Nika Pharmaceuticals 9-Day RSI Related Terms
NIKA vs ESPR, AMPH, BIOA: 9-Day RSI Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Nika Pharmaceuticals's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nika Pharmaceuticals 9-Day RSI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Nika Pharmaceuticals's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Nika Pharmaceuticals's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nika Pharmaceuticals (NIKA) has a 9-Day RSI of 76.69 as of Jul. 29, 2026. According to the industry distribution chart, Nika Pharmaceuticals ranks #1014 out of 1047 companies in the Drug Manufacturers industry, placing it in the top 96.8%.
Is Nika Pharmaceuticals' 9-Day RSI too high?
Nika Pharmaceuticals' current 9-Day RSI is 76.69. The Drug Manufacturers industry median 9-Day RSI is 45.80. Nika Pharmaceuticals' value of 76.69 is 67.4% above this industry median. Based on the distribution chart, Nika Pharmaceuticals ranks #1014 out of 1047 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Nika Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Nika Pharmaceuticals' 9-Day RSI compare to ESPR and AMPH?
According to the Drug Manufacturers industry distribution chart, Nika Pharmaceuticals ranks #1014 out of 1047 companies for 9-Day RSI. This places Nika Pharmaceuticals in the lower half of its industry. The industry median 9-Day RSI is 45.80. Nika Pharmaceuticals' value of 76.69 is 67.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Drug Manufacturers company?
The median 9-Day RSI among Drug Manufacturers companies is 45.80, based on 1,047 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nika Pharmaceuticals's current 9-Day RSI of 76.69 is 67.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median 9-Day RSI is 45.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nika Pharmaceuticals's current 9-Day RSI is 76.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nika Pharmaceuticals stock overvalued right now?
Nika Pharmaceuticals (NIKA) has a current 9-Day RSI of 76.69. The current 9-Day RSI is 76.69 and 67.4% above the Drug Manufacturers industry median of 45.80. Nika Pharmaceuticals' overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Nika Pharmaceuticals (NIKA), the current 9-Day RSI is 76.69 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nika Pharmaceuticals Inc is a company involved in development and distribution of a variety of pharmaceutical products, including dietary supplements and antiviral drugs. It has acquired the exclusive rights for production and distribution of the dietary supplements Physiolong and Carotilen, as well as the drug TNG, which has been clinically tested on AIDS patients.
12GF Score
Get the complete analysis for NIKA
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NIKA has been successfully added to your 
